| Jul 9 |
Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth
|
| Jul 2 |
FDA grants priority review for Neurocrine’s crinecerfont NDAs
|
| Jul 1 |
FDA sets target action dates for Neurocrine drug applications
|
| Jul 1 |
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
|
| Jun 28 |
How Medicare drug price negotiations could hit pharma stocks
|
| Jun 17 |
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
|
| Jun 14 |
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
|
| Jun 12 |
Those who invested in Neurocrine Biosciences (NASDAQ:NBIX) five years ago are up 55%
|
| Jun 3 |
Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
|
| Jun 3 |
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
|
